Publicacións en colaboración con investigadores/as de Mayo Clinic (24)

2023

  1. Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes

    Human molecular genetics, Vol. 32, Núm. 16, pp. 2646-2655

2022

  1. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604

  2. Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex

    Journal of Hepatology, Vol. 76, Núm. 4, pp. 921-933

2021

  1. Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis

    Gastroenterology, Vol. 160, Núm. 3, pp. 889-905.e10

  2. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

2018

  1. Cholangiocytes in health and disease: From basic science to novel treatments

    Biochimica et Biophysica Acta - Molecular Basis of Disease

  2. MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma

    Hepatology, Vol. 68, Núm. 2, pp. 561-573

  3. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. Global position paper on cardiovascular regenerative medicine

    European Heart Journal

  2. New potential targets for the treatment of biliary diseases

    Current Drug Targets

  3. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

  4. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

    Hepatology, Vol. 66, Núm. 4, pp. 1125-1143

2016

  1. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease

    American Journal of Human Genetics, Vol. 98, Núm. 6, pp. 1193-1207

2015

  1. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

    Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961

2014

  1. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression

    American Journal of Pathology, Vol. 184, Núm. 1, pp. 110-121

  2. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

2013

  1. Alcohol consumption on pancreatic diseases

    World Journal of Gastroenterology, Vol. 19, Núm. 5, pp. 638-647

  2. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases

    Hepatology, Vol. 58, Núm. 1, pp. 409-421